Published in Clin Cancer Res on November 19, 2010
Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet (2011) 3.82
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol (2012) 1.11
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer (2013) 1.06
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol (2012) 0.99
A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLoS One (2012) 0.98
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One (2013) 0.97
Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci (2013) 0.96
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer (2015) 0.93
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia (2012) 0.92
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol (2012) 0.90
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs (2014) 0.84
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. J Cancer Res Clin Oncol (2016) 0.82
Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL (2014) 0.82
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine. EPMA J (2015) 0.80
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol (2015) 0.80
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J (2016) 0.79
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. Urol Clin North Am (2015) 0.78
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism. Cardiovasc Res (2015) 0.77
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Sci Rep (2016) 0.76
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One (2015) 0.75
Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials. Genome Med (2011) 0.75
Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Transl Androl Urol (2012) 0.75
Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up? Nat Rev Urol (2015) 0.75
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res (2016) 0.75
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget (2016) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget (2017) 0.75
Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. Oncotarget (2017) 0.75
Population modelling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics and clinical outcome in sunitinib-treated cancer patients. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
The risk of cancer in users of statins. J Clin Oncol (2004) 3.01
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2006) 2.56
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum (2007) 2.36
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum (2006) 2.00
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev (2004) 1.84
Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res (2008) 1.81
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics (2012) 1.65
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 1.60
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57
Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A (2004) 1.56
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49
Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev (2004) 1.48
Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy (2010) 1.48
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol (2005) 1.41
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. Leuk Res (2007) 1.38
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol (2010) 1.34
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer (2007) 1.31
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs (2014) 1.24
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res (2008) 1.24
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nat Genet (2013) 1.21
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood (2002) 1.21
Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat (2011) 1.20
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol (2009) 1.19
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother (2008) 1.18
Targeted therapy for renal cell cancer: current perspectives. Discov Med (2010) 1.18
Implementation of a computerized physician medication order entry system at the Academic Medical Centre in Amsterdam. Pharm World Sci (2003) 1.17
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer (2010) 1.17
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer (2008) 1.16
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther (2005) 1.15
Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother (2011) 1.14
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res (2009) 1.14
Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist (2006) 1.14
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13
Epidemiology of Norwalk-like virus infections in cattle in The Netherlands. Vet Microbiol (2003) 1.13